Women with a particularly aggressive form of early stage (primary) breast cancer may miss out on optimal treatment which may include chemotherapy and trastuzumab (Herceptin) as a result of untimely or missing HER2-status test results, according to doctors responding to the results from a North of England Cancer Network audit of HER2-testing today.
More...
Linear Mode
